Reviewing Tectonic Therapeutic (NASDAQ:TECX) and Cardium Therapeutics (OTCMKTS:CRXM)

Cardium Therapeutics (OTCMKTS:CRXM) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Institutional and Insider Ownership

62.6% of Tectonic Therapeutic shares are held by institutional investors. 49.8% of Cardium Therapeutics shares are held by company insiders. Comparatively, 38.0% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Cardium Therapeutics and Tectonic Therapeutic, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardium Therapeutics	0	0	0	0	0.00
Tectonic Therapeutic	1	0	6	1	2.88

Tectonic Therapeutic has a consensus price target of $80.57, indicating a potential upside of 189.77%. Given Tectonic Therapeutic’s stronger consensus rating and higher probable upside, analysts plainly believe Tectonic Therapeutic is more favorable than Cardium Therapeutics.

Valuation & Earnings

This table compares Cardium Therapeutics and Tectonic Therapeutic”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardium Therapeutics	N/A	N/A	N/A	N/A	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15 million	($4.05)	-6.87

Profitability

This table compares Cardium Therapeutics and Tectonic Therapeutic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardium Therapeutics	N/A	N/A	N/A
Tectonic Therapeutic	N/A	-26.88%	-25.83%

Summary

Tectonic Therapeutic beats Cardium Therapeutics on 5 of the 8 factors compared between the two stocks.

About Cardium Therapeutics

Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.

About Tectonic Therapeutic

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.